摘要
对N-甲基-D-天冬氨酸(NMDA)受体拮抗剂临床研究失利的原因及NMAD受体亚单位研究的一些最新进展进行了综述。包括以下几个方面:(1)NMDA受体与脑损伤的关系;(2)NMDA受体拮抗剂作为脑中风临床治疗药物的争议;(3)亚单位选择性NMDA受体拮抗/激动剂作为新型脑中风治疗药物的研究趋势。对于NMDA受体拮抗剂作为脑中风治疗药物的开发前景进行了展望:NMDA受体拮抗/激动剂研究已经积累了一定的理论研究资料,目前的研究虽遇挫折,但放弃NMDA受体拮抗剂的研究为时尚早,希望能寻求一种新的给药途径来解决临床治疗时间窗的问题。
This paper summarizes the reasons why N-methyl-D-aspartate （NMDA） receptor antagonists failed in clinical trials, and recent progresses in the study of NMDA receptor subtypes, including the relationships between NMDA receptor and the brain injury; disputes on NMDA receptor antagonists used in the therapy of stroke, and the trend in NMDA receptor subtypes specific antagonists/agonists as novel anti-stroke agents. The potentials of NMDA receptor antagonists are also discussed. Anti-stroke effects of NMDA receptor antagonists have been proven by so many investigations that it is not ready to give up, despite of the existence of failures in the studies. We look forward one new approach in order to find solution to the problems related to the therapeutic time window in the clinical applications.
出处
《中国药科大学学报》
CAS
CSCD
北大核心
2006年第2期111-113,共3页
Journal of China Pharmaceutical University
